WHC is still in active development. Read this to understand our approach.
depiction of NEGYEDYHPHMHGK-UHFFFAOYSA-N.svg
isomerdesign

PMA

Check on isomerdesign

pubchem

4-Methoxyamphetamine

Check on pubchem

drugmap

Beta-methoxyamphetam...

Check on drugmap

wiki

Para-Methoxyamphetam...

Check on wiki

Data

InChI: InChI=1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3

Synonyms: UNII-OVB8F8P39Q,NSC-32757,FORMOTEROL FUMARATE RELATED COMPOUND G [USP IMPURITY], 1-(4-methoxyphenyl)propan-2-amine,paramethoxyamphetamine,Death [Street Name],BDBM50024209,(+/-)-p-Methoxy-alpha-methylphenylethylamine,(+-)-p-Methoxy-alpha-methylphenylethylamine,AKOS005536031,NSC32757, 50505-80-1,PMA,p-Methoxyamphetamine,D,L-p-methoxyamphetamine,J434.573H,1-(4-Methoxyphenyl)-2-propanamine,chloroprednisone21-acetate,(-)2-(4-Methoxy-phenyl)-1-methyl-ethylamine,Benzeneethanamine, 4-methoxy-alpha-methyl- (9CI),1-(4-methoxyphenyl)propan-2-amine,Phenethylamine, p-methoxy-.alpha.-methyl-,alpha-methyl-4-methoxyphenethylamine,2-Amino-1-(4'-methoxyphenyl)propane,4-Methoxy-alpha-methylbenzeneethanamine,Q230005, 1-p-Methoxyphenyl-2-propylamine,(1S)-2-(4-METHOXYPHENYL)-1-METHYLETHYLAMINE,(+-)-1-(p-Methoxyphenyl)-2-aminopropane,AB51426,SCHEMBL264634,SCHEMBL721008,OVB8F8P39Q,p-Methoxy-.alpha.-methylphenethylamine, (+-)-p-Methoxyamphetamine,1-(4-Methoxybenzyl)ethylamine,alpha-Methyl-beta-(p-methoxyphenyl)ethylamine,Phenethylamine, p-methoxy-alpha-methyl- (6CI,7CI,8CI), Para-Methoxyamphetamine,64-13-1,(.+/-.)-p-Methoxyamphetamine,(d,l)-4-Methoxyamphetamine,Formoterol Fumarate Impurity G,Formoterol fumarate related compound G,1-(4-Methoxyphenyl)propan-2-amine,(+-)-p-Methoxyamphetamine,Benzenethanamine,4-methoxy-.alpha.-methyl-(.+/-.)-,2-(4-Methoxyphenyl)-1-methylethylamine, p-Methoxyamphetamine,2-(4-Methoxy-phenyl)-1-methyl-ethylamine(PMA),(+/-)-4-Methoxyamphetamine,beta-methoxyamphetamine, 2-Amino-1-(4'-methoxyphenyl)propane,DEATH,DL-p-Methoxy-.alpha.-methylphenethylamine, 23239-32-9, beta-methoxyamphetamine,HSDB 7594, 1-p-Methoxyphenyl-2-aminopropane,4-methoxyamfetamine,FORMOTEROL FUMARATE DIHYDRATE IMPURITY G [EP IMPURITY],P-methoxyamfetamine,FT-0690314, p-Methoxy-alpha-methylphenethylamine,(+/-)-1-(p-Methoxyphenyl)-2-aminopropane,DR. DEATH, 1-(4-Methoxybenzyl)ethylamine,DL-p-Methoxy-alpha-methylphenethylamine,Phenethylamine, p-methoxy-alpha-methyl-,DEA No. 7411,J213.549C,STK664902,4-MA,1-p-Methoxyphenyl-2-aminopropane,Benzeneethanamine, 4-methoxy-.alpha.-methyl-,Chicken Yellow [Street Name],.alpha.-Methyl-.beta.-(p-methoxyphenyl)ethylamine,MB01555, para-methoxyamphetamine,CHEMBL278663,AB70588,NSC 32757,DTXSID7040578,(+-)-4-Methoxyamphetamine, DEA No 7411, (+-)-p-Methoxy-alpha-methylphenethylamine,(+/-)2-(4-Methoxy-phenyl)-1-methyl-ethylamine,Chicken Powder [Street Name],1-p-Methoxyphenyl-2-propylamine,2-(4-Methoxy-phenyl)-1-methyl-ethylamine,1-(4-methoxyphenyl)-2-aminopropane,EINECS 200-577-0, 64-13-1, paramethoxyamphetamine,(+/-)-p-Methoxyamphetamine,(-)-2-(p-methoxyphenyl)-1-methylethylamine,PMA (PSYCHEDELIC),(.+/-.)-4-Methoxyamphetamine,(.+/-.)-p-Methoxy-.alpha.-methylphenethylamine,(2RS)-1-(4-methoxyphenyl)propan-2-amine,4-Methoxyamphetamine,DB01472,[2-(4-methoxyphenyl)-1-methyl-ethyl]-amine,para-methoxyamphetamine,(S)-(+)2-(4-Methoxy-phenyl)-1-methyl-ethylamine,benzeneethanamine, 4-methoxy-alpha-methyl-, DL-p-Methoxy-alpha-methylphenethylamine,p-Methoxy-alpha-methylphenethylamine,Benzeneethanamine, 4-methoxy-.alpha.-methyl-, (.+/-.)-,(R)-(-)2-(4-Methoxy-phenyl)-1-methyl-ethylamine,4-METHOXYAMFETAMINE [MART.],NCI60_002842,(.+/-.)-1-(p-Methoxyphenyl)-2-aminopropane, NSC 32757,Phenethylamine, p-methoxy-.alpha.-methyl-, (.+/-.)-,N-(2-(p-methoxyphenyl)-1-methylethyl)amine,4-MeO-AMP,NCGC00168268-01


Estimated data

Solubility: -1.369 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 90.6% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.